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Abstract
Postpartum women with an opioid use disorder (OUD) are at high risk for treatment
disengagement, leaving them vulnerable to overdose and death between seven and twelve
months postpartum. Intensive case management programs have been proposed as an effective
strategy to reduce barriers and increase treatment engagement among postpartum women. The
purpose of this study was to evaluate program outcomes of postpartum women with OUD and
the health outcomes of their infants when engaged in an intensive case management program
postpartum. The study was a retrospective review of secondary data collected on 221 postpartum
mothers and 225 infants of mothers who were enrolled in an intensive case management program
in Tennessee between May 1, 2019, and May 5, 2020. Chi-squares were computed to examine
timing of engagement during pregnancy, maternal treatment outcomes and infant health
outcomes including neonatal abstinence syndrome (NAS), birth weight, gestational age, and
length of stay. The mean prenatal program engagement was 109 days (SD = 67.6); 16.7% (n =
37) enrolled during the first trimester, 37.6% (n = 83) in the second trimester, and 45.7% (n =
101) in the third trimester. At the time of data collection, of the 221 mothers in the study, 45.2%
(n = 100) were identified as engaged, 14.5% (n = 35) were identified as graduated, and of the
mothers who graduated, 78.1% (n = 25) were noted as engaged in MAT. Of 225 infants 28.9% (n
= 65) had a positive NAS status, mean birth weight was 6.5 lbs. (SD = 1.20); mean gestational
age was 38.3 weeks (SD = 1.80) and mean length of stay was 8.19 days (SD = 9.8). The findings
of this study identified that engaging mothers during pregnancy in a program designed to meet
their unique challenges positively impact both the mother and infant outcomes, regardless of the
timing during pregnancy.
Key words: intensive case management, neonatal abstinence syndrome, opioid addiction,
opioid crisis, opioid use in pregnant women, postpartum addiction.
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Introduction and Background
The opioid epidemic has profoundly impacted vulnerable populations, specifically
pregnant and postpartum women, and their infants. The number of pregnant and postpartum
women with opioid use disorder (OUD) has quadrupled from 1999 to 2014 (Haight et al., 2018).
In 2019, the Centers for Disease Control and Prevention (CDC) found 6.6% of women reported
using prescription opioids pain relievers during their pregnancy. Among women using opioids
during pregnancy, 36.5% reported having obtained opioids from a non-healthcare provider and
using opioids for reasons other than pain relief (Ko et al., 2020).
OUD during pregnancy and postpartum increases the risk of adverse maternal and
neonatal outcomes. Adverse maternal outcomes include depression, anxiety, hepatitis, human
immunodeficiency virus (HIV), and miscarriage (Ko et al., 2020; Mittal & Suzuki, 2017;
Renbarger et al., 2020; Wright et al., 2012). Adverse neonatal outcomes include intrauterine
growth restriction, placental abruption, preterm labor, stillbirth, and neonatal abstinence
syndrome (NAS) (Gopman, 2014; Harter, 2019; Maeda, 2014; Substance Abuse and Mental
Health Services Administration [SAMHSA], 2018a). OUD's direct impact on maternal mortality
is difficult to ascertain due to differences in state reporting requirements, details included or not
included on death certificates, and potential concerns regarding physician liability (Dorman et
al., 2016; MacDorman et al., 2016). However, recent studies that included a review of the death
certificates of mothers who had given birth within 12 months of death revealed a 76.9% increase
in opioid associated deaths from 1999 to 2017 (Mitra et at., 2020). Likewise, Gemmill et al.
(2019) noted that maternal mortality associated with OUD doubled between 2007 and 2016.
Additionally, the opioid epidemic has increased the number of infants born with NAS.
The CDC reported a 433% increase in infants with NAS between 2004 and 2014 (Jilani et al.,
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2019). Infants with NAS have an increased risk of congenital disabilities, hospitalizations,
cognitive impairment, and a lower risk of intelligence, social maturity, and poor psychomotor
abilities (Mittal & Suzuki, 2017).
Despite the well-documented unique challenges that exist for women with OUD seeking
treatment and pregnancy care, pregnancy has a powerful influence on women's motivation to
seek OUD treatment, and women are more likely to initiate OUD treatment during pregnancy
(Goodman et al., 2020). Increased access to care, insurance coverage, and social services are
other motivating factors during pregnancy for women with OUD to seek and access treatment
(Vestal, 2019; Wilder et al., 2015). These influential factors are evident by the reported increase
in admission rates to treatment programs among pregnant mothers with OUD during 1992 and
2012, from 2% to 28% (Martin et al., 2015).
A survey conducted by the National Surveys on Drug Use and Health (NSDUH)
discovered that 52.5% of pregnant women ages 15 to 44 years were covered by Medicaid when
they entered a treatment program for OUD (Smith & Lipari, 2017). The standard of treatment for
pregnant and postpartum mothers with OUD is an evidence-based treatment approach that
combines medications with counseling and behavioral therapy known as medication-assisted
treatment (MAT) (American College of Obstetricians and Gynecologists [ACOG], 2017).
Unfortunately, while pregnancy increases access to healthcare through Medicaid
coverage, the coverage for a pregnant woman expires sixty days after delivery (Vestal, 2019;
Wilder et al., 2015). The loss of insurance coverage, coupled with the responsibilities of
providing newborn care, often results in a woman's withdrawal or discontinuation of treatment
for OUD (Gordon et al., 2020; McNeely et al., 2018; Wilder et al., 2015). Postpartum mothers
enrolled in MAT with Medicaid coverage are the most vulnerable for relapse if Medicaid is
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discontinued (Vestal, 2019; Wilder et al., 2015). Research has shown that relapse is higher
during the postpartum period than any other time in the childbearing cycle, with the most critical
time during 7 and 12 months postpartum (ACOG, 2017; Normile et al., 2018; Schiff et al.,
2018).
Furthermore, sustained engagement in MAT requires pregnant and postpartum mothers
to have stable transportation, childcare, and availability during the traditional workday (Frist,
2019; Le et al., 2019; Meinhofer et al., 2020; Nordenfors & Höjer, 2017). Unfortunately, women
with OUD frequently present with unique barriers, including polysubstance use, sexual abuse,
domestic violence, inadequate social support, and stigma. These barriers are compounded by
pressures unique to the postpartum mother including, unstable housing, lack of reliable childcare,
and transportation (Frist, 2019; Hodgins et al., 2019; Meinhofer et al., 2020 Normile et al.,
2018). Sadly, the failure of traditional treatment programs to meet postpartum women's unique
needs increases the risks of treatment disengagement, which subsequently may increase the risks
of opioid overdose and death (Normile et al., 2018). Identifying these unique barriers of
postpartum women lead the Substance Abuse and Mental Health Services Administration
(SAMHSA) to develop a women-centered approach to treatment that promote intensive case
management support for the psychosocial and medical vulnerabilities of women who are
engaging in treatment for SUD during pregnancy and postpartum (SAMHSA, 2018b).
Intensive case management programs have been emerging in substance use programs
treating postpartum mothers with OUD (Hodgins et al., 2019; Krans et al., 2018; Thomas et al.,
2017). This innovative care strives to bridge the gap between traditional substance abuse
treatment and a pregnant or postpartum mother's unique need by focusing on stress reduction and
stabilizing the mother through relationship building. Intensive case management programs
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identify tangible barriers such as childcare, transportation, and housing; and offers wrap-around
services as needed. Additionally, case managers are engaged in outreach efforts, including home
visits, accompanying mothers at doctor's appointments, or engaging family support. The
intensive case management program's interaction is flexible and adapted based on the mother's
needs. For example, during periods of crisis, contact with the mother is more frequent, and when
the mother is stable, contact is less regular. (Frist, 2019; Meinhofer et al., 2020; Mittal & Suzuki,
2017; Normile et al., 2018; Tarasoff et al., 2018).
Problem Statement
Pregnant women with OUD experience multiple compounding and overlapping barriers
to care that compromise sustained engagement in treatment and increase the risk of myriad poor
health outcomes for both mother and child. Intensive case management programs have improved
engagement in treatment by providing specialized services directed at the unique needs of
pregnant women (Frist, 2019; Kroelinger et al., 2020; Meinhofer et al., 2020; Mittal & Suzuki,
2017; Normile et al., 2018; Tarasoff et al., 2018). However, treatment disengagement in the
postpartum period remains a risk factor for poor maternal and infant health outcomes. The extent
to which earlier engagement in treatment that includes intensive case management predicts
continued engagement postpartum period is not well studied.
Purpose
The purpose of this project is to determine the effects of early engagement in an intensive
case management program on postpartum engagement and infant health outcomes among
postpartum women with an opioid use disorder during a 12-month period.
Hypotheses
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The project leader hypothesizes that longer exposures to intensive case management,
defined as earlier engagement during pregnancy, will be positively associated with postpartum
treatment engagement and improved neonatal health outcomes.
Review of Evidence
Intensive case management programs improve health outcomes for patients with chronic
diseases by uniquely addressing social determinants of health that create obstacles to care access,
self-efficacy, and adherence (Cajita et al., 2017; Vanderplasschen, et al., 2007). The complexity
of managing chronic disease requires new strategies, tools, and process of care to achieve the
“triple aim” of healthcare: improving patients’ health quality and outcomes and the quality of
patients’ lives; increasing access to healthcare services; and reducing healthcare costs by
preventing or minimizing the effects of a disease (Bardhan et al., 2020; Palmer, et al., 2018;
Timpel, P. et al., 2017; Wagner, 2019). The targeted, individualized blend of social services and
medical care provided by intensive case management programs have improved health for
patients with chronic illnesses such as diabetes, chronic obstructive pulmonary disease (COPD),
end-stage renal disease (ESRD) and HIV (Chow & Wong, 2010; Shacam et al., 2018; Timpel, et
al., 2017; van Eeden et al., 2017; Wagner, 2019).
OUD is a chronic illness with physiological changes and periods of relapse; studies have
shown engagement in intensive case management increases engagement in treatment in pregnant
and postpartum mothers and improves the mothers’ and infants’ health (Andrews et al., 2018;
Krans et al., 2018; Le et al., 2019; Nordenfors & Höjer, 2017; Staudt, 2018; Thomas et al.,
2017).
The services offered by an intensive case management program directly respond to
known barriers to treatment engagement for pregnant and postpartum mothers experiencing
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OUD, including stigma reduction, access to social services, transportation, and childcare
assistance (Andrews et al., 2018; Moreland & McRae-Clark, 2018; Nordenfors & Höjer, 2017;
Tarasoff et al., 2018; Thomas et al., 2017).
An excellent example of the impact of care coordination on the health outcomes for
pregnant and postpartum mothers with OUD was completed by Hodgins et al. (2019). Hodgins
and his colleagues studied the Collaborative Outreach and Adaptable Care at Hallmark Health
(COACHH). The evaluation of the COACHH program revealed a positive correlation between
treatment retention and frequent contact with a woman-centered approach to care (Hodgins et al.,
2019). The achievement of regular communication was accomplished via frequent interactions
by heightened awareness of challenges, gaps in care, and health-related social needs of pregnant
and postpartum mothers among the health care team (Hodgins et al., 2019).
Social Determinants of Health
Stigma
A well-documented treatment barrier among pregnant and postpartum women with OUD is
stigma, internal or external (Espinet et al., 2016; Normile et al., 2018; Tauger, 2018). Internal
stigma results from enormous feelings of guilt and fear related to opioid use during pregnancy,
which creates intense feelings of negative self-image, shame, and low self-esteem (Luoma et al.,
2014). At the same time, pregnant and postpartum women with OUD experience external stigma
which related to bias and judgmental attitudes regarding opioid use during pregnancy from
providers, family, or friends (Renbarger et al., 2020). Several studies have identified the
importance of incorporating a supportive professional relationship that fosters trust, openness,
and caring to motivate and encourage continued treatment engagement (Mahoney, K. et al.,
2019; Nordenfors & Höjer, 2017; Renbarger et al., 2020; Staudt, 2018).
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Milligan et al. (2010) discovered that developing a therapeutic relationship is fundamental
in supporting women to make a positive change. Additionally, counselors perceived as nonjudgmental were identified by postpartum women as a critical part of making a positive change
(Andrews et al., 2018).
Among other studies, the importance of the healthcare providers being genuinely interested
in the women and her circumstances, remembering personal details, and inquiring about personal
information fosters trust and a sense of caring, which has shown to increase the women's
willingness to be honest, and increase engagement in treatment (Gopman, 2014; Howard, 2015;
Krans et al., 2018; Renbarger et al., 2020). Some studies identified the importance of the
provider's engagement in training to increase knowledge of addiction, the obstacles postpartum
women face, and to address any bias present among the healthcare professionals caring for
postpartum mothers with OUD to reduce stigma among healthcare professionals (Byrne &
Tanesini 2015; Hodgins et al., 2019; Seybold et al., 2014).
Lastly, other studies have shown a favorable outcome by incorporating peer advocates into
treatment programs. A peer advocate is a support person who has had similar experiences and
can provide non-professional, non-clinical recovery support services (Myrick & Vecchio, 2016).
Postpartum women reported reduced feelings of stigmatism and increased feelings of trust,
security, and acceptance with a peer advocate (Fallin-Bennett et al., 2020; Goodman et al., 2020;
Howard, 2016; McLeish & Redshaw, 2017; Reif et al., 2014). Additionally, pregnant and
postpartum mothers described a more positive experience and better outcomes such as reduced
relapse rates, increased retention in treatment programs, and improved relationships with
providers and social services when paired with a peer advocate (Reif et al., 2014).
Access to Social Support
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Social support can be defined as verbal and nonverbal communication between recipients
and providers to facilitate coping strategies and reduce uncertainty about the situation, the self,
and enhances the perception of personal control (Nordenfors & Höjer, 2017; Reif et al., 2014).
Social support is necessary for pregnant and postpartum mothers experiencing OUD. These
mothers are at an increased risk of social isolation due to difficulty relating to others, past
conflicts and broken relationships, and fear of prosecution and are less likely to utilize social
support systems (Reif et al., 2014; Shearer et al., 2019;). Many postpartum women with OUD
struggle to construct a new life; however, leaving old unhealthy relationships and developing
new relationships is often vital for continued engagement in OUD treatment. Several studies
identified the importance of support from professionals and peer advocates, to function as role
models and helped mothers build new relationships and more robust networks (Goodman et al.,
2020; Haffajee et al., 2018; Nordenfors & Höjer, 2017).
In addition to needing social support to build new relationships, some studies have
identified the support of navigating child welfare and the legal system as a motivating factor for
postpartum mothers to remain engaged in an intensive case management program (Tarasoff et
al., 2018; Wright et al., 2012). Research has indicated the significance of developing confident,
open, and trusting relationships with professionals in treatment centers, welfare offices, or an
intensive case management program (Hodgins et al., 2019; Nordenfors & Höjer, 2017). Because
mothers with OUD are frequently at risk for losing custody of their children, retaining, or
regaining custody is a crucial motivating factor in treatment engagement. Having assistance
navigating these complex systems and stressful interactions is vital (Powis et al., 2000; Tarasoff
et al., 2018).
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Women with OUD are more likely to discontinue engagement in MAT during the
postpartum period than during pregnancy (ACOG, 2017; Normile, 2018). Contributing factors to
higher rates of relapse during this time include losing custody of the child, the shame and stigma
associated with having an infant exposed to opioids, and increased anxiety experienced with
caring for an inconsolable infant (Schiff et al., 2018; Schiff et al., 2020). Therefore, it is critical
to provide postpartum mothers with access to social support during this vulnerable time.
Transportation
A frequently cited barrier for pregnant and postpartum women with OUD to accessing
care for OUD is transportation (Krans et al., 2018; Kuo et al., 2013; Staudt, 2018; Tarasoff et al.,
2018; Wright et al., 2012). While this is a known barrier, it is a frequent reason postpartum
woman become disengaged in treatment for OUD and has been illustrated in both large urban
and rural areas (Krans et al., 2018; Kuo et al., 2013). Reliable transportation is a key factor for
mothers to engage or remain engaged in OUD treatment, prenatal care, postpartum care, and
well-child visits.
Several studies have shown that providing bus passes or cab fares improved engagement
in outpatient treatments (Kuo et al., 2013; Meinhofer et al., 2020; Saunders et al., 2018; Staudt,
2018; Tarasoff et al., 2018; Wright et al., 2012).
Likewise, Gopman (2014) discovered the importance of employing peer support to help
navigate transportation resources. Coordination of referrals or completion of applications has
shown decreased barriers to transportation and increased engagement in treatment.
Childcare
Another reoccurring barrier to the mother's adherence to OUD treatment during the
postpartum period is reliable childcare (Andrews et al., 2018; Jansson et al., 2007; Krans et al.,
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2018; Saunders et al., 2018). Several studies cited that treatment services, inpatient, and
outpatient, fail to provide onsite childcare for postpartum mothers, the lack of available childcare
services deters mothers from seeking needed treatment for OUD (Powis et al., 2000; Saunders et
al., 2018; Tarasoff et al., 2018; Thomas et al., 2017; Wright et al., 2012).
Research has also acknowledged a higher number of engaged mothers in treatment for
OUD when mothers can remain with their children (Schiff et al., 2020; Staudt, 2018).
Interestingly, the SAMHSA's program for pregnant and postpartum women allows mothers to
bring babies to inpatient rehab and has onsite childcare in the outpatient settings (SAMHSA,
2018b).
Early Engagement
Analysis of mothers with OUD have identified that early engagement in MAT during
pregnancy improves engagement in MAT throughout the postpartum period and reduces the
vulnerability to their social situation, and the risk of relapse during the first year postpartum
(Andrews et al., 2018; Hodgins et al., 2019; Moreland & McRae-Clark, 2018). However, few
studies have exhibited if a correlation exist between early engagement in an intensive case
management program during pregnancy and retention in MAT treatment throughout the
postpartum period (Espinet et al., 2016; Staudt, 2018).
Theoretical Model
The American Society of Addiction Medicine (2019) defines addiction as a chronic
health condition characterized by episodes of relapses and compulsive drug-seeking behaviors
that continue despite harmful consequences and long-lasting changes in the brain. In 2017,
Timpel, et al. examined the importance of a chronic care model that included an individual’s
social and emotional needs as vital to successful self-management. The study highlighted that
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most patients with chronic diseases have unmet needs that are non-medical and cited evidence of
the improved effectiveness of interventions that include community-based collaborative care
supported by intensive case management (Le et al., 2019; Timpel et al., 2017; Wright et al.,
2012).
Professor Peter Schwarz of the University of Dresden led the MANAGE CARE study
group, the group consisted of 70 national Diabetes Associations in 47 countries across the
European region. The study began in 2013 and lasted for three years, focusing on shaping policy,
growing public awareness, motivating health improvement, and encouraging sharing best
practice for diabetic care throughout the European region (International Diabetes Federation,
2020).
The MANAGE CARE Study Group developed the MANAGE CARE MODEL (MCM);
this innovative care model focuses on incorporating specific individual needs and frequently
adjusting care to meet those needs. The MANAGE CARE Study Group utilized the Chronic
Care Management (CCM) model as the framework to create the MCM (Timpel et al., 2020). The
CCM was developed by Wagner in 1990 and has been considered a cornerstone to improve care
delivery for patients with a chronic condition (Wagner, 2019). However, recent studies have
shown that the effectiveness and applicability of the CCM in complex and diverse patient
populations is limited (Grover & Joshi, 2015; Palmer et al., 2018).
Through literature review and collaboration with health care providers, the MANAGE
CARE Study Group suggested improvements to the CCM by adding elements that denoted
collaboration between health care and social care systems. This adaptation to the CCM,
acknowledges barriers to community resources and social services that are beyond the patients’
individual capacity but also fall outside of the reach of the healthcare system, leaving patients
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vulnerable and underserved. Additionally, the MCM emphasizes a multidisciplinary approach to
care to deliver specialized services based on individual needs. The final MCM model includes
seven dimensions of integrated care including (1) Care Delivery Strategy, (2) Participation,
Prevention and Health Promotion, (3) Health and Social Care System, (4) Health Professionals,
(5) Living Environment and Broad Community Engagement, (6) Patients with Diabetes (Risk)
and (7) Improved Integrated Care (Timpel et al., 2020).
While the MCM has previously been tested in adults with diabetes, the model was
selected for this scholarly project as an innovative approach to treating OUD as a chronic disease
utilizing a comprehensive team to address the specific needs of the pregnant and postpartum
mothers with OUD (Timpel et al., 2017; Timpel et al., 2020). However, its components have yet
to be tested in pregnant and postpartum mothers with OUD.
This model supports collaboration by integrating the functions of the health care system
and the social care system's functions to reduce barriers for vulnerable and high-risk populations
(Timpel et al., 2020). For example, this model supports medically assisted treatment (MAT) for
OUD while also supporting the need for childcare, transportation, housing assistance, or
employment assistance. This model addresses the patient's medical and non-medical needs to
provide wrap-around services that reduce known barriers that contribute to treatment
disengagement.
The care delivery strategy includes multiple disciplines with specialized training prepared
to deliver specialized services for pregnant and postpartum mothers with OUD (Timpel et al.,
2020). For example, a multidisciplinary team incorporates peer advocates, counselors, social
workers, and nurses to meet pregnant or postpartum mother's medical and social needs with
OUD.
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The multidisciplinary team and a pregnant or postpartum mother with OUD engage in
productive and targeted high touch interactions that respond to specific needs. For example, if a
mother needs a ride to MAT, help find a job, or childcare, the multidisciplinary team, responds to
the need immediately and frequently to meet these needs. When a system can be responsive to
meet the unique needs that are identified as barriers, the rate of relapse is reduced. Creating a
responsive care model creates a barrier reduction that allows women to be more successful in
their recovery and sustain their chronic disease's maintenance phase.
Additionally, the MCM model utilizes all the community resources, the model
incorporates the patients' living environment, integrates family, and community support to create
a holistic approach to care (Timpel et al., 2020). This model also incorporates the mothers' and
babies' social needs such as sober living, transportation needs, childcare needs, and housing and
employment assistance to provide strength for mothers living with OUD.
Each of the dimensions defined in this model contributes to incorporating integrated care;
to improve the mothers' experience, improve the health outcomes of both the mother and the
baby and to reduce costs and increase awareness of OUD prevalence among pregnant and
postpartum mothers.
Project Design
Overview
This scholarly project was a secondary analysis of retrospective patient utilization data to
determine the effects of early engagement in an intensive case management program on maternal
and infant health outcomes for pregnant and postpartum women with an opioid use disorder for
12 months. This project was verified as exempt by the Belmont University IRB on July 22, 2020.
Clinical Setting
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The study was conducted using longitudinal observational de-identified data sets obtained
from StrongWell in Tennessee. StrongWell is an outreach program of 180 Health Partners. The
StrongWell program is an intensive case management program specializing in meeting the
unique barriers of pregnant and postpartum mothers with OUD. The StrongWell approach to care
immediately fills the gaps for pregnant and postpartum mothers with OUD by meeting mothers
where they are. The program offers an accessible, convenient, and flexible team of
compassionate, experienced counselors, doctors, nurses, and peer advocates (Fist, 2019).
StrongWell serves approximately 350 pregnant and postpartum mothers with OUD in
Tennessee. The time of enrollment in the program varies, but the average is during the middle of
the second trimester (Fist, 2019). Enrollment specialists are in several offices to connect and
instantly engage the mother, thereby reducing the stress of seeking care and then stabilize the
mother by addressing social determinants, lifestyle, and environment (Frist, 2019).
This intensive case management program offers non-medical services such as childcare,
transportation, housing assistance, or social support (Towle, 2019). Since the program's
implementation in 2016, TN reported a significant downward trend in babies born with NAS; in
2107, 1015 babies were born with NAS, and in 2018, 881 babies were born with NAS.
Additionally, the state reported a decrease in the birth of premature babies, shorter hospital stays
for babies with NAS, increased prenatal, postpartum, and well-child visits, and an increase in
MAT engagement among postpartum mothers (Towle, 2019).
Project Population
The patient utilization of the de-identified data for this study consisted of postpartum
women over 18 years with an opioid use disorder admitted to StrongWell between May 1, 2019,
and May 5, 2020. The study included women who were enrolled at least one day before the
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delivery of their baby. Data on postpartum mothers who were enrolled in the StrongWell
program after delivery or were not being treated for primary opioid addiction were excluded
from the sample. Additionally, data on infants with no NAS status identified were excluded as
this was a primary outcome of interest.
Sources of Data/Data Collection Instruments
The researcher extracted data for this project from two sources. One source included deidentified data retrieved from insurance claims from inpatient, outpatient, and prescription claims
data from four different insurance providers. The insurance providers included Amerigroup, TN
Blue Cross, Blue Shield- Blue Care, Blue Shield-Commercial, and TN United Healthcare
Community Plan. The second source of de-identified data was extracted from StrongWell's
electronic medical records and included admission data, case management encounters, and
program engagement status data. The insurance company assigns all clients a unique case
number upon admission to StrongWell. This unique case number allows data from the insurance
billing claims to be linked to patient utilization data collected at StrongWell for program
evaluation. The data was de-identified before being transferred as an Excel file created by
StrongWell's information technology manager to the project leader through email.
The project leader linked patient utilization data to each patient's unique case number.
The first Excel spreadsheet contained all encounters between the StrongWell care team and the
mother. This data included the mother’s care plan status, which identified engagement duration;
listed as; “lost to follow up”, “graduated”, “postpartum < 3 months”, “postpartum 3-5 months”,
“postpartum 6-8 months”, and “postpartum > 8 months” program status: was listed as
“graduated”, “lost to follow up”, or “engaged” , and the total number of days enrolled in the
program, reported as the total number of days enrolled prior to birth and postpartum. The second
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Excel spreadsheet contained the mothers' medication histories. The medications were identified
by drug name and date filled at the pharmacy. The third Excel spreadsheet identified information
related to the baby, including the baby's date of birth, weight in pounds and ounces, length of
hospital stays in days, baby's status of NAS reported as positive or negative, gestational age at
birth and insurance plan.
Data Collection Process/Procedures
The data was organized and cleaned in Microsoft Excel. Initially, the data set included
service utilization records of 280 mothers and infants, 280 singletons and six twins. After
identifying and removing the data sets not meeting the stated inclusion criteria, there were 221
mothers and 225 infants that remained in the study. The percentage of missing data was
calculated for each survey measure. The missing data for the length of stay was 8.6% and 9.7%
for birth weight; all other data was less than 5%.
To identify if the birth weight and length of stay were missing at random, the project
manager created new variables and assigned a 0 if data was present and 1 if the data was
missing. An independent T-test was conducted to test if the grouping variable and outcome
variables were significant. There was no significance identified among the variables. The project
manager concluded the missing data were missing at random and proceeded to add the series
mean for the missing data for both birth weight and length of stay.
The project examined the correlation between one independent variable and five
dependent variables. The independent variable, length of enrollment, was reported as the number
of days enrolled in the program; this variable was transformed into a categorical variable to
reorganize the number of days engaged by trimester: “first trimester” (>188 days), “second
trimester” (92-187 days) and “third trimester” (1-91 days).
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The dependent variables for the mothers included “current engagement status”, defined
categorically as “engaged”, “graduated” or “postpartum treatment drop out”, “engagement
duration”. Engagement duration defined categorically as “postpartum treatment dropout”,
graduated”, “engaged less than three months postpartum”, “engaged three to five months
postpartum”, “engaged six to eight months postpartum” or “engaged greater than eight months
postpartum.”
The dependent infant variables included presence or absence of neonatal abstinence
syndrome (NAS) reported as a dichotomous variable (0 = no, 1 = yes), birth weight reported as
ratio variable expressed in ounces; number of days in the hospital expressed as a numerical
variable, and gestational age was expressed as a numerical variable as number of weeks.
To measure length of enrollment prenatally on postpartum engagement, the project leader
created a dichotomous (0 = graduated and engaged, 1 = postpartum treatment dropout). The
project leader transformed the mother's status and sub-status variables into a numerical value for
analysis using the IBM SPSS software.
The project leader then entered the data into the IBM SPSS software; the project leader
used a chi-square tests to individually assess the relationship between the length of enrollment
and postpartum engagement duration, length of enrollment and current engagement status, length
of enrollment and MAT engagement and lastly length of enrollment and NAS. The significance
level for all chi square test is ∝ = .05. A one-way ANOVA was conducted to evaluate the
association between length of enrollment and length of hospital stay, babies' weight, gestational
age at birth, and engagement postpartum. The significance values for the ANNOVA was set ∝ =
.05.
Results
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Data from service utilization of 221 women and 225 infants were included in the
analysis. Descriptive data for the sample of women enrolled in intensive case management is
summarized in Table 1 and details regarding insurance status at time of enrollment is depicted in
figure 8. Most of the women lived in Middle TN (51%, n = 115). All women were insured, with
the majority having a state-funded plan (99.2%, n = 219). Mean program engagement before
birth was 109 days (SD = 67.6), 16.7% enrolled during the first trimester, 37.6% engaged in the
second trimester and 45.7% in the third trimester. Mean program engagement during the
postpartum period was 118 days (SD = 2.2), or 4.2 months.
Descriptive data for infant health outcomes included NAS status, birth weight, length of
stay (LOS), and gestational age at the delivery time. The mean gestational age was 38.2 weeks
(SD= 1.80). The mean birth weight was 6.5 pounds (SD = 1.20). The mean LOS was 8.19 days
(SD = 9.80). Negative NAS status was identified in 71.1% (n = 160) of the infants. Descriptive
data for infants of women enrolled in an intensive case management program in Tennessee is
summarized in Table 2.
To evaluate length of postpartum engagement six outcomes of care were identified and
summarized in Figure 2. Of the 221 mothers in the study, 89 (40.3%) were identified as program
dropout, 32 (14.5%) had graduated from the program, 35 (15.8%) were engaged less than three
months postpartum, 21 (9.5%) were engaged 3-5 months postpartum, 31 (14%) were engaged 68 months postpartum, and 13 (5.9%) were engaged greater than eight months postpartum.
To evaluate current program engagement status three categories were identified and
summarized in Figure 3. These categories were described as program dropout, graduated and
engaged. Of the 221 mothers 89 (40.3%) program dropouts, 100 (45.2%) were engaged
collection, and 32 (14.5%) had graduated at the time of the data collection.
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Lastly, MAT engagement was identified among 146 (66.1%) of the mothers during
postpartum. Details of MAT engagement are depicted in Figure 4.
Program Outcomes
Length of Postpartum Engagement
To examine if there is an association between length of treatment engagement during pregnancy
and length of postpartum engagement, a chi-square test was conducted. Details for length of
postpartum engagement are depicted in Table 3, Table 4, and Figure 13. The results are as
follows; χ2 (10) = 31,921, p < .001. The post hoc z test revealed that were was significant
evidence to show that mothers who graduated from the program were more likely to be enrolled
during the first trimester (6.8%, n = 15) when compared to mothers who graduated in third
trimester. (3.2%, n = 7). Additionally, the post hoc z test revealed that there was significant
evidence to show that mothers who enrolled during the third trimester were more likely to be
reported as postpartum treatment dropouts (23.1%, n = 51) when compared to mothers engaged
in the first trimester (3.6%, n = 8) and the second trimester (13.6%, n = 30). There was also
evidence show that engaging mothers in the third trimesters had highest rates of sustained
engagement during 6-8 months postpartum (6.8%, n = 15) and greater than eight months (2.7%,
n = 8).
Current Program Status
To measure if there is an association between length of treatment engagement by
trimester before birth and current program status, a chi-square test was conducted. Details
regarding current program status are depicted in Table 5, Table 6, and Figure 3. There was
significant evidence to concluded that an association exists between length of engagement by
trimester before birth and current program status., χ2 (4) = 29,235, p < .001. There was
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significant evidence to show that sustained engagement during postpartum was higher among
mothers who engaged during the second trimester (19.4%, n = 43) and the third trimester
(19.5%, n = 43) when compared to mothers engaged during the first trimester (6.5%, n = 14).
MAT Engagement
To measure an association between length of enrollment and MAT engagement status a
chi-square test of independence. Details for postpartum MAT engagement are noted in Table 7,
Table 8, Table 11 and Figure 4. The relation between the number of days enrolled before birth
and engagement in MAT was statistically significant, χ2 (2,) = 62,690, p < .001. There was
significant evidence to conclude that engagement during the second trimester yielded the highest
engagement in MAT during postpartum (33%, n = 73). To further evaluate engagement in MAT,
a chi- square was conducted on mother who graduated and MAT engagement at the time of the
data collection. This analysis revealed that of the 35 mothers who graduated, 78.1% (n = 25)
were engaged in MAT, and of the mothers engaged 64% (n = 64) were engaged in MAT.
Infant Health Outcomes
NAS Status
A chi-square analysis was performed to examine the association between length of
enrollment prior to birth and NAS status. There was a significant evidence that a correlation exits
between length of program engagement before pregnancy and NAS status of the infant, χ2 (2)
=7,701, p = .021. The analysis revealed that mothers who engaged during the third trimester
were more likely to have a baby with positive NAS status when compared to negative NAS
status. Mothers who engaged in the first trimester 2.7% (n = 6) of the infants were positive for
NAS, mothers who engaged in the second trimester 8.9% (n = 19) of the infants were positive for
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NAS, and the mothers who engaged in the third trimester 17.2% (n = 38) of the infants were
positive for NAS. NAS details are depicted in Table 9, Table 10, and Figure 6.
Infant Weight, Length of Hospitalization, Gestational Age at Birth
A one-way between subject's ANOVA was conducted to compare the effects of length of
engagement on the baby's weight, length of hospitalization, or gestational age at birth. The
ANOVA showed a prominent effect on enrollment in an intensive case management program
before delivery on the baby's birth weight, F (2, 200) = 4.53, p = .012. The post hoc analysis
using Bonferroni indicated that enrollment during the first trimester had infants with a higher
birth weight with an average birth weight of 110.8 oz when compared to enrollment during the
third trimester. There was no significant association noted effect between timing of engagement
and length of stay F (2, 196) = .594, p = .553, or gestational age at birth F (2, 220) = 2.419, p =
.091. The results of the ANOVA are detailed in Table12, Table 13, Table 14, and Table 15.
Discussion
The study analyzed if an association existed between the length of program engagement
by trimester during pregnancy in an intensive case management program and the program
outcomes among mothers with OUD during postpartum and their infants' health outcomes. The
study's strength was the large sample size, which allowed the project leader to examine the
relationship between enrollment length on key program status measurements and infant health
outcomes.
Program Status
The study demonstrated that mothers who graduated from the program were more likely
to be enrolled during the first trimester and had lower program dropout rates during the first six
months postpartum when compared to mothers enrolled in the third trimester. Nevertheless,
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evidence revealed the importance of engaging mothers in the second and third trimesters, as
demonstrated by higher rates of sustained postpartum engagement during 6 to 8 months
postpartum and greater than 8 months postpartum. Continued postpartum engagement is
clinically significant because research has shown sustained treatment engagement has a positive
impact on long term health outcomes for the mother and the child (Chan, & Trant, 2018; Seay,
2020).
While there is limited data on sustained engagement during and beyond one year after
delivery, it is well documented that mothers who struggle with OUD have unique barriers that
traditional treatment programs fail to address, leading to an increase in the risk of treatment
disengagement during the postpartum period (Andrews et al., 2018; Moreland & McRae-Clark,
2018; Nordenfors & Höjer, 2017; Normile et al., 2018; Tarasoff et al., 2018; Thomas et al.,
2017). Sobriety and treatment engagement during the postpartum period are essential because
even without the presence of NAS, opioid use hampers the mother's attunement and
responsiveness to the baby's emotional needs, which can disrupt the ability to form a secure
attachment between the mother and the baby (Mirick & Steenrod, 2016). Children who grow and
develop in a household with addiction face a number of mental and physical health consequences
and often exhibit negative behaviors internalizing (e.g., negative moods or emotional states) and
externalizing behaviors (e.g., disinhibition and impulsivity) (Chan, & Trant, 2018; Seay, 2020).
An encouraging discovery in this study was the clinical significance of engaging in an
intensive case management program at any time of pregnancy. MAT is the gold treatment
standard for pregnant women who experience OUD and evidence has shown that early
engagement in MAT is associated with improved neonatal health outcomes including less severe
neonatal withdrawal, decreased preterm birth, low birth weight, placental abruption, and lower
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rates of active OUD when treatment is initiated during pregnancy (Ray et al., 2021; Sutter et al.,
2019). This study highlighted the impact of an intensive case management program and
increased engagement in MAT postpartum.
Research has also revealed that mothers often struggle with the loss of state-funded
insurance coverage, which often results in a woman's withdrawal or discontinuation of OUD
treatment (Gordon et al., 2020; McNeely et al., 2018; Wilder et al., 2015). In this study, many
women had a state-funded insurance plan (99.2%). The data showed a steady decline in length of
engagement postpartum with only 19.9% (n = 44) of the mothers were engaged in the program
after 6 months postpartum. This decline in engagement could reflect barriers to treatment posed
by insurance coverage. Although it is difficult to associate insurance coverage loss with a decline
in program engagement, it is an interesting finding and supports the literature. Sadly, postpartum
mothers experience increased susceptibility around 7 to 12 months postpartum and increased
rates of relapse have been reported during this time (ACOG, 2017; Normile et al., 2018; Schiff et
al., 2018).
Infant Health Outcomes
The StrongWell program focuses on reducing barriers to successful OUD management
for mothers. This study's findings revealed that engaging mothers at any time during pregnancy
motivated the mothers to make positive changes that led to better health outcomes for the mother
and the infant. Among all the babies in the study, 28.5% were diagnosed with NAS at the time of
delivery. This finding is clinically significant because babies born with NAS are more medically
fragile and the mother experiences increased bias from providers, family, and peers. The
experience of this situation has the potential to pose additional stress to a mother who is recently
sober. To effectively handle this additional pressure, the mother will need extra support to
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sustain engagement in treatment and to be emotionally available for her new baby. While this is
an interesting finding, further research is needed to identify if those mothers were engaged in
MAT treatment before enrollment in StrongWell's program.
This research's findings also support the findings that babies with NAS have a longer
length of stay in the hospital. The average length of stay for babies with NAS in this study was
15.7 days, supporting the conclusion that NAS is associated with increased health care costs,
exposure to stigma and blame for opioid use, and exposure to unsupportive nurses who advocate
for the baby to be placed in foster care instead of encouraging mother-baby bonding (Jilani et al.,
2019).
Implications for Practice
Despite the SAMHSA, recommendations to develop a women-centered approach to
treatment that incorporates a comprehensive program responsive to the psychosocial and medical
vulnerabilities of pregnant and postpartum mothers with OUD, there continues to be a gap in
women-centered programs to support their unique needs (SAMHSA, 2018b).
Additional research needs to be conducted to strengthen the treatment for mothers with
OUD. The research needs to capture the experiences of mothers engaged in an intensive case
management program, analyze specific beneficial elements of the program, and outline new
approaches to women-centered programs. According to Tarasoff and colleagues (2018),
integrated programs that encompass services focused on decreasing barriers, holistic service
delivery and social services support is associated with positive outcomes, however mothers’
perceptions of care and perceived barriers remain poorly understood.
There is evidence to suggest that women who enroll in treatment late in pregnancy are
both stigmatized and underserved, their babies are more medically fragile and require more
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intensive care. Treatment programs that reflects this evidence and persists in meeting women
where they are, and offering them the support they need promotes positive maternal and child
health outcomes.
While it remains critical to care for mothers while they are pregnant, longitudinal
research that extends beyond the postpartum period into early childhood development will
illuminate the long-term effects of both sustained recovery and untreated OUD on mothers and
their children (Ray et al., 2021).
Limitations
Limitations of this study include de-identified secondary longitudinal data, and
incomplete data. Additionally, the data was limited to the experience of one intensive case
management program in Tennessee.
Measuring the impact of this program is challenging. The data collected was limited
to insurance claims data and program data obtained at the time the patient was seen. There was
limited demographical data collected and no specific factors associated with harm reduction were
identified. The additional data would add value to the research and support additional womencentered programs. Hodgins and colleagues (2019) suggested success should be measured in
terms of harm reduction and programs should focus on engagement rather than abstinence.
Finally, the insights regarding compliance with MAT is another limitation of the study.
This study identified postpartum treatment engagement as mothers who had an active care plan
at the time the data was collected, and while MAT engagement was reported when the insurance
paid for the medication. Therefore, it cannot be concluded that the mothers were compliant with
MAT therapy. Additionally, it cannot be concluded that postpartum treatment dropout leads to
relapse or discontinuation of MAT. Since there is no contact with the dropouts, the reason for

THE HEALTH IMPACT OF INTENSIVE CASE MANAGEMENT

31

dropping out and continuation of MAT treatment is unknown. It is important to remember the
administration of MAT was not monitored by StrongWell, and it is essential to consider that the
mothers who dropped out of the StrongWell program may have continued to receive MAT at the
recovery center.
Conclusion
The opioid epidemic has profoundly impacted pregnant and postpartum mothers and their
children. MAT is the gold standard of treatment for anyone with an OUD, and sustained
engagement in treatment is also a positive predictor of improved long-term health outcomes
(ACOG, 2017).
This scholarly project demonstrated the positive effects an intensive case management
program has on the mother and infant's health outcomes regardless of the timing of enrollment
during pregnancy. While pregnancy is a time for motivation and change, continued engagement
during the postpartum period is essential to maintain sobriety postpartum and to improve the
mother and her infant's health outcomes. It is encouraging that the study identified mothers who
engaged during the third trimester demonstrated more extended treatment engagement after
delivery. Continued treatment engagement is a clinically significant discovery and supports
literature findings regarding the importance of overcoming barriers to improve treatment
engagement in pregnant and postpartum mothers. Additionally, it is essential to acknowledge
that infants born to mothers with OUD who are engaged in an intensive case management
program have lower rates of NAS at birth.
This scholarly project's findings suggest that engagement in an intensive case
management program on mothers with OUD and their infants has a substantial impact on
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program outcomes such as graduation and MAT engagement and infant health outcomes such as
reduced NAS status, higher birth weights, and less preterm births.
While the numbers of pregnant mothers with OUD is increasing, there needs to be an
alarming concern for the health of the unborn baby and the long-term health outcomes of
mothers with OUD, and the consequences of children growing up in such environments. There
are no studies that identify the impact of an intensive case management program on mothers and
their children's long-term health outcomes. There is a need for additional research on the effects
of engaging in an intensive case management program on long-term health outcomes for both the
mother and baby during the postpartum period.
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Figure 1.
Applying the Managed Care Model to pregnant and postpartum mothers with OUD
(International Diabetes Federation, 2020).
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Figure 2.
Length of Postpartum Engagement
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Figure 3.
Current Engagement Status
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Figure 4.
Maternal Engagement in MAT Postpartum
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Figure 5.
Percent of Maternal Engagement by Trimester before Birth
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Figure 6.
Percentages of Program Outcomes per Length of Engagement by Trimester
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Figure 7.
NAS Status of Infant and Association to Time of Engagement During Pregnancy
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Figure 8.
Insurance Status at Time of Enrollment
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Figure 9.
Average Birth Weight by Length of Engagement per Trimester
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Figure 10.
Average Gestational Age at Birth per Length of Engagement by Trimester
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Figure 11.
Average Length of Hospitalization per Length of Engagement by Trimester
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Figure 12.
Percentages of MAT Engagement per Length of Engagement per Trimester
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Figure 13.
Percentages of Length of Postpartum Enrollment per Length of Engagement by Trimester

57

THE HEALTH IMPACT OF INTENSIVE CASE MANAGEMENT

58

Table 1.
Descriptive data of women enrolled in an intensive case management program in Tennessee (N = 221).

n

%

Mean

Std.
Deviation

Skewness

Kurtosis

Statistic

Statistic

Std. Error

Statistic

Statistic

Std. Error

Statistic

Std. Error

Total Number of Days
Enrolled Before Birth

211

109

4.54

67.63

.185

.164

-1.157

.326

1st Trimester
2nd Trimester
3rd Trimester
Total Number of Days
Enrolled During
Postpartum

37
83
101
458

118

4.89

72.7

1.42

.164

3.488

.326

Insurance
TN ANTH Amerigroup
TN BCBS Blue Care
TN BCBS BlueCross
BlueShield
COMMERICAL
TN UHC Community Plan

221
78
47
2

35.3
21.3
.9

94

42.5

Region
TN- Middle
TN –West
TN-East

221
114
9
98

51.6
4.1
44.3

16.7
37.6
45.7
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Table 2.
Descriptive of infants of women enrolled in an intensive case management program in Tennessee (N = 225).

n
NAS
Positive
Negative

Statistic
225
65
160

%

Mean

Std.
Deviation

Skewness

Kurtosis

Statistic

Std. Error

Statistic

Statistic

Std. Error

Statistic

Std. Error

28.9
71.1

Length of
Stay

199

8.19

.695

9.80

3.75

.172

18.8

.343

Gestational
Age

223

38.3

.121

1.80

-.795

.163

2.11

.324

Total weight
in oz

203

104

1.36

19.3

-.131

.171

.383

.340
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Table 3.
Results of Chi Square and Post Hoc Z Test for Length of Treatment Engagement by Trimester and Length of Postpartum Engagement

Enrollment
Before
Birth

Postpartum
Treatment
Dropout
n
%

Graduated
n
%

PP < 3
Months
n
%

PP 3-5
Months
n
%

PP 6-8 Months
n
%

PP > 8
Months
n
%

Total
n
%

1st Trimester

8a

3.6

15a

6.8

4a

1.8

3a, b

1.4

4a

1.8

3a, b

1.4

37

16.7

2nd Trimester

30a

13.6 10a

4.5

16b

7.2

11a

5

12a

5.4

4a

1.8

83

37.6

3rd Trimester

51a
89

23.1 7b
40.3 32

3.2 15a, b
14.5 35

6.8
15.8

7a,b
21

3.2
9.5

15a, b
31

6.8
14

6a, b
13

2.7
5.9

101
221

45.7
100

Total

χ2

31,921 <.001

Note: Each subscript letter denotes a subset of Mother's Care Plan Status categories whose column proportions do not differ
significantly from each other at the p = .05 level
Table 4.
Percentages of Length of Postpartum Engagement by Length of Engagement by Trimester

Enrollment Before
Birth

Postpartum
Treatment
Dropout
%

Graduated
%

PP < 3 Months
%

PP 3-5
Months
%

PP 6-8 Months
%

PP > 8 Months
%

Total
%

1st Trimester

3.6

6.8

1.8

1.4

1.8

1.4

16.7

2nd Trimester

13.6

4.5

7.2

5

5.4

1.8

37.6

23.1
40.3

3.2
14.5

6.8
15.8

3.2
9.5

6.8
14

2.7
5.9

45.7
100

rd

3 Trimester
Total

p
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Table 5.
Results of Chi Square and Post Hoc Z Test for Length of Treatment Engagement and Program Outcomes
Postpartum
Treatment
Dropout
n
%
Enrollment
Before
Birth

1st Trimester

8a 3.6

Engaged
n
%

Graduated
n
%

n

14a

15b

6.8

37

16.7

19.4 10b

4.5

83

37.6

3.2
14.5

101
221

45.7
100

6.3

2nd Trimester

30a 13.6 43a

3rd Trimester

51a 23.1 43a,b 19.5 7a
89 40.3 100 45.2 32

Total

Total
%

χ2

p

29,235

<.001

Note: Each subscript letter denotes a subset of Program Outcomes categories whose column proportions do not differ significantly
from each other at the p = .05 level

Table 6.
Percentages of Program Outcomes per Length of Enrollment by Trimester

Enrollment Before Birth

Postpartum
Treatment
Dropout
%

Engaged
%

Graduated
%

1 Trimester

3.6

6.3

6.8

16.7

2nd Trimester

13.6

19.4

4.5

37.6

23.1
40.3

19.5
45.2

3.2
14.5

45.7
100

st

rd

3 Trimester
Total

Total
%
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Table 7.
Results of Chi Square and Post Hoc Z Test for Length of Treatment Engagement and MAT Engagement
MAT
n
Enrollment
Before Birth

1st Trimester

%

No MAT
n
%

Total
%

n

34a 23.3 3b

4

37

16.7

2 Trimester

73a 50

10b

13.3

83

37.6

3rd Trimester

39a 26.7 62b
89 100 32

82.7
100

101
221

45.7
100

nd

Total

χ2

p

62,690

<.001

Note: Each subscript letter denotes a subset of MAT Engagement categories whose column proportions do not differ significantly from
each other at the p = .05 level
Table 8.
Percentages of MAT Engagement per Length of Enrollment by Trimester

MAT
n
Enrollment
Before
Birth

Total

%

n

No MAT
%

n

Total
%

1st Trimester

34a 15.4 3b

1.4

37

16.7

2nd Trimester

73a 33

4.5

83

37.6

3rd Trimester

39a 17.6 62b
89 66.1 32

10b

28.1 101
33.9 221

45.7
100

χ2

p

62,690

<.001
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Table 9.
Results of Chi Square and Post Hoc Z Test for Length of Treatment Engagement and NAS Status

n
Enrollment
Before Birth

Positive NAS
%

Negative
NAS
n
%

n

Total
%

1st Trimester

6a 2.7

31a

13.8

37

16.7

2nd Trimester

20a 8.9

64a

28.4

84

37.6

3rd Trimester

39a 17.3 65a
65 28.9 160

28.9
71.1

104
225

45.7
100

Total

Table 10.
Percentages of NAS per Length of Program Engagement

Enrollment Before Birth

Positive NAS

Negative NAS

%

%

2.7

13.8

2 Trimester

8.9

28.4

3rd Trimester

17.3
28.9

28.9
71.1

1st Trimester
nd

Total

χ2

p

7,701

.021
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Table 11.
Results of Chi-Square of with-in groups comparison of MAT Engagement and Current Program Status
MAT
%
Graduated
Discharged

n

%

78.1
64

25
57

64

64

Engaged

No MAT
n
%
21.9
7 100
36
32 100
36

36 100

Total
n
32
89
100
221

Table 12.
One-Way ANOVA results for Length of Engagement and Baby’s Weight
Source
Between Groups
Within Groups
Total

df

SS

MS

F

p

2

2964.656

1248.328

4.535

0.012

222

72561.028

326.851

224

75525.685

THE HEALTH IMPACT OF INTENSIVE CASE MANAGEMENT

65

Table 13.
One-Way ANOVA results for Length of Engagement and Length of Hospital Stay
Source

df

SS

MS

F

p

2

102.545

51.273

0.602

0.549

222

18919.575

85.223

224

19022.121

Between Groups

Within Groups
Total

Table 14.
One-Way ANOVA results for Length of Engagement and Gestational Age
Source
Between Groups
Within Groups
Total

df

SS

MS

F

p

2

15.534

7.767

2.419

0.091

220

706.341

3.211

222

721.874
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Table 15.
Percentages of Infant Outcomes by Length of Enrollment per Trimester

Enrollment Before
Birth

Birth weight (lbs. & oz)
%

LOS
%

6.86

7.26

38.4

2 Trimester

6.61

7.72

38.5

3rd Trimester

6.27

8.89

37.9

1st Trimester
nd

Gestational Age
%

